Eli Lilly and Company
Eli Lilly Announces Underwriting Agreement for Note Issuance
Summary
On February 7, 2024, Eli Lilly and Company entered into an underwriting agreement for the issuance and sale of $6.45 billion aggregate principal amount of its 4.500% Notes due 2027, 4.500% Notes due 2029, 4.700% Notes due 2034, 5.000% Notes due 2054, and 5.100% Notes due 2064. The notes were issued pursuant to an Indenture dated February 1, 1991, and an officers' certificate setting forth the terms of the Notes. The offering of the Notes was registered on a Registration Statement on Form S-3 (File No. 333-262943). The closing of the offering occurred on February 9, 2024.
Profitelligence Alerts
Get alerts for LLY
Be first to know when Eli Lilly and Company files with the SEC.
Filing Categories
Exhibits (4)
Advertisement
About Eli Lilly and Company
Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.
Official SEC Documents
Advertisement